Single Nucleotide Polymorphisms (SNPs) are a component of Transcriptional Control Factor (TCF) binding sites, which either activate or repress gene expression. Over 30 proprietary SNPs have been identified which disrupt TCF binding domains, such as cats, NF1, CRE, ATF, CREB (cJun), AP1, NF1, and TCF-2 alpha. Genes affected include TGF-beta, TGF-beta receptor II, nitric oxide synthase, von Hippel-Lindau tumor suppressor gene, and endothelium-1. Viral Therapeutics has 11 patents pending.
Comparison of SNP analysis of hundreds of patient samples, with their complete medical histories, have determined that SNP haplotype polymorphisms are linked to noninsulin-dependent diabetes mellitus (NIDDM), hypertension (HT), end-stage renal disease (ESRD), cardiovascular disease, and cancer, among other illnesses.
Focused Approach To Pharmacogenomics
VTI leverages this intellectual property along with a focus on specifically related pathway genes to provide clients with the ability to define:
Critical diagnostic indicators:
- Identifying responders vs. nonresponders
- Identify toxicity vs. therapeutic benefit
- Validate new targets for therapy
- Link SNPs to protein expression with an experienced team
- Utilize a 10,000 sample DNA library with medical histories
Discovery approach:
- Defined Patient and Control Populations
- Identify Candidate Gene(s)
- SNP Discovery in Promoters
- SNP Scoring
- In Silico Haplotype construction
- Disease Association Statistics